Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA BIOMED TO PRESENT AT
BIOTECH AND HEALTHCARE INVESTOR ROADSHOW
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) announces that Stuart Roberts, Head of Investor Relations for Prima, will provide an overview of
the company at the Biotech & Healthcare Investor Roadshow hosted by Canary Networks on May 20 and 21, 2015.
Roberts will present at both
events for the May roadshow in Melbourne from 1 PM till 3 PM on Wednesday 20 May, 2015 at Rydges Hotel, 181 Exhibition Street; and in Sydney from 1 PM till 3 PM on Thursday 21 May, 2015 at the Royal Automobile Club of Australia, 89
Investors wishing to attend these events must register themselves beforehand. If you wish to register, please visit the Canary Networks
website, www.canarynetworks.com.au.
Prima s presentation slides will be available on the company website prior to these events.
About Canary Networks
Established in 2009, Canary
Networks is a specialist investor and corporate communications business providing a unique platform for ASX listed companies to engage with the financial and investment communities.
Prima BioMed is a globally active
biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to
market for patients and to maximise value to shareholders.
Prima s pipeline of products includes IMP321 based on the LAG-3 immune control mechanism
which plays a vital role in the regulation of the T cell immune response. IMP321 is its most clinically advanced product, a T cell immunostimulatory factor (APC activator) for cancer chemoimmunotherapy which has completed early Phase II trials. A
number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
For further information please contact:
Global Head of Investor Relations
+61 (0) 447 247 909; stuart.roberts@primabiomed.com.au
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN: 90 009 237 889